DEA Revokes California MD's Drug Handling License
Published Date: 9/30/2025
Notice
Summary
Dr. David Payne from California lost his DEA license to handle controlled substances because he’s no longer allowed to prescribe or participate in federal health programs. He didn’t ask for a hearing, so the DEA made the decision final. This means he can’t legally prescribe or manage controlled drugs starting now, impacting his medical practice and federal program involvement.
Analyzed Economic Effects
2 provisions identified: 0 benefits, 2 costs, 0 mixed.
DEA Registration Revoked for David Payne
The Drug Enforcement Administration revoked David Payne, M.D.'s DEA Certificate of Registration No. BP3113963 and denied any pending applications to renew, modify, or obtain additional registration in California. The Order takes effect October 30, 2025, and follows findings that his California medical license is suspended.
14-Year Federal Health Program Exclusion
The record shows David Payne, M.D. was mandatorily excluded from participation in Medicare, Medicaid, and all Federal health care programs effective May 20, 2024, for a period of fourteen years. That exclusion is an independent basis the DEA relied on to revoke his registration.
Your PRIA Score
Personalized for You
How does this regulation affect your finances?
Sign up for a PRIA Policy Scan to see your personalized alignment score for this federal register document and every other regulation we track. We analyze your financial profile against policy provisions to show you exactly what matters to your wallet.
Key Dates
Department and Agencies
Related Federal Register Documents
2026-10128 — Revision of Applications for Manufacturing and Procurement Quotas
The DEA wants to update how companies apply for permission to make and buy certain controlled drugs and chemicals. These changes will make the rules clearer, help prevent drug shortages, and ensure enough supply for medical and scientific needs. If you’re a manufacturer or involved in this process, get ready to follow new steps and share your thoughts by July 20, 2026.
2026-10380 — Schedules of Controlled Substances: Placement of Diphenidine in Schedule I
The DEA wants to put diphenidine, a drug, into Schedule I, which means it will be treated like the most tightly controlled substances. This change affects anyone who makes, sells, studies, or owns diphenidine, adding strict rules and penalties. You’ve got until June 25, 2026, to share your thoughts before the new rules might kick in.
2026-10253 — Schedules of Controlled Substances: Temporary Placement of 2-Fluorodeschloroketamine in Schedule I
Starting May 22, 2026, the DEA is putting 2-fluorodeschloroketamine (2-FDCK) into Schedule I, meaning it’s now treated like the most dangerous drugs. This affects anyone who makes, sells, or uses it, adding strict rules and serious penalties. The temporary ban lasts two years, giving the government time to decide if it should stay permanent.
2026-10090 — Exempt Chemical Preparations Under the Controlled Substances Act
The Drug Enforcement Administration (DEA) reviewed and decided on applications for special chemical mixtures that don’t fall under strict drug rules, covering requests from July 2025 to March 2026. Some mixtures got approved, others denied, and a few listings were fixed from earlier notices. If you’re involved with these chemicals, you’ve got until July 20, 2026, to share your thoughts—no fees or big costs involved, just your voice!
2026-09566 — Schedules of Controlled Substances: Placement of CUMYL-PEGACLONE in Schedule I
Starting May 13, 2026, the DEA officially puts CUMYL-PEGACLONE—a chemical that can be risky—into Schedule I, the strictest drug category. This means anyone making, selling, or using it now faces tough rules and penalties. This move helps the U.S. follow international drug laws and keeps communities safer without any new fees or costs.
2026-08588 — Bulk Manufacturer of Controlled Substances Application: Patheon API Inc.
Patheon API Inc. wants to make large amounts of special research drugs like dimethyltryptamine and psilocybin. This affects researchers and companies involved in clinical trials, with a chance to comment or ask for a hearing by July 6, 2026. No money changes are mentioned, but this move could speed up important medical studies.
Previous / Next Documents
Previous: 2025-19053 — Self-Regulatory Organizations; Financial Industry Regulatory Authority, Inc.; Notice of Partial Amendment No. 1 to Proposed Rule Change To Amend the FINRA Capital Acquisition Broker (“CAB”) Rules
FINRA wants to update its Capital Acquisition Broker (CAB) rules to let brokers work with more types of investors and handle private securities deals more flexibly. These changes affect brokers, investors, and companies selling unregistered securities, aiming to make deals smoother and clearer. The SEC is reviewing the updates, with decisions expected soon, but no immediate money changes are announced.
Next: 2025-19056 — Self-Regulatory Organizations; Fixed Income Clearing Corporation; Notice of Filing and Immediate Effectiveness of Proposed Rule Change To Amend GSD Rule 42 (Suspension of Rules) and MBSD Rule 33 (Suspension of Rules in Emergency Circumstances)
The Fixed Income Clearing Corporation (FICC) is updating its emergency rules to make it clearer when and how they can pause certain operations during unusual situations. This change affects firms using FICC’s Government Securities and Mortgage-Backed Securities services, helping everyone stay safe and sound when things get tricky. The new rules took effect right away on September 25, 2025, with no extra costs involved.